Mass Spectrometry-Based Identification of MHC-Associated Peptides

Area of Science:

• Immunology
• Proteomics
• Mass Spectrometry

Background:

• Neoantigen-based immunotherapies offer improved patient outcomes but rely on accurate cancer-specific antigen detection.
• Current mass spectrometry-based neoantigen detection is hindered by diverse and heterogeneous isolation protocols.
• Limited neoantigen quantities on cell surfaces necessitate highly sensitive detection methods.

Purpose of the Study:

• To summarize and evaluate existing protocols for the extraction and identification of major histocompatibility complex (MHC) class I and II peptides.
• To assess the appropriateness of isolation procedures and instrumental parameters for neoantigen detection.
• To highlight the critical role of starting material quantity in neoantigen analysis.

Main Methods:

• Review and comparison of mild acid elution (MAE) and immunoprecipitation (IP) protocols for neoantigen isolation.
• Evaluation of instrumental sensitivity and accuracy requirements for detecting low-abundance neoantigens.
• Analysis of available proteomics tools for neoantigen discovery and the necessity of experimental validation.

Main Results:

• Protocol heterogeneity complicates inter-laboratory and inter-study comparisons of neoantigen data.
• Low neoantigen abundance often restricts studies to cell cultures due to tissue limitations.
• While computational tools aid discovery, experimental validation remains essential for neoantigen characterization.

Conclusions:

• Standardizing neoantigen isolation protocols is crucial for reliable and comparable results in cancer immunotherapy research.
• Advancements in instrumentation sensitivity are vital for detecting scarce neoantigens from patient samples.
• A comprehensive approach combining optimized experimental methods and computational analysis is needed for effective neoantigen discovery and validation.